R. Vidal

发表

Diagnosis and management of von willebrand disease in Spain

V. Jiménez‐Yuste, J. Mateo, J. Batlle, 2018 .

Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project

V. Jiménez‐Yuste, J. Mateo, J. Batlle, 2018, PloS one.

Molecular and clinical profile of von Willebrand disease in Spain (PCM–EVW–ES): Proposal for a new diagnostic paradigm

V. Jiménez‐Yuste, J. Mateo, J. Batlle, 2015, Thrombosis and Haemostasis.

Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients

V. Jiménez‐Yuste, J. Mateo, J. Batlle, 2017, Haematologica.

Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort

V. Jiménez‐Yuste, J. Mateo, J. Batlle, 2020, Thrombosis and Haemostasis.

Docosahexaenoic acid–A new therapeutic approach to peroxisomal‐disorder patients

M. Pineda, J. Conill, R. Vidal, 1993, Neurology.

Direct vitamin k antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation

E. Askari, P. Llamas, Á. Hidalgo-Vega, 2014, BMC Health Services Research.

Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA

V. Jiménez‐Yuste, J. Mateo, J. Batlle, 2018, Haematologica.

[Association between venous thrombosis and dyslipidemia].

R. Mata, G. Ene, C. Miranda, 2014, Medicina clinica.